These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3283 related items for PubMed ID: 30902885

  • 1. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX.
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ, Sung PS, Lee GW, Cho S, Kim SM, Kang BY, Hur W, Yang H, Lee SK, Lee SH, Jung ES, Seo CH, Ahn J, Choi HJ, You YK, Jang JW, Bae SH, Choi JY, Yoon SK.
    Int J Mol Sci; 2021 Apr 29; 22(9):. PubMed ID: 33946835
    [Abstract] [Full Text] [Related]

  • 4. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H.
    Gut; 2017 Jan 29; 66(1):157-167. PubMed ID: 26452628
    [Abstract] [Full Text] [Related]

  • 5. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W, Liu Y, Yan Z, Yang H, Sun W, Yao Y, Chen Y, Jiang R.
    J Immunother Cancer; 2020 Jun 29; 8(1):. PubMed ID: 32581055
    [Abstract] [Full Text] [Related]

  • 6. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q, Zhou W, Yin S, Zhou Y, Chen T, Qian J, Su R, Hong L, Lu H, Zhang F, Xie H, Zhou L, Zheng S.
    Hepatology; 2019 Jul 29; 70(1):198-214. PubMed ID: 30810243
    [Abstract] [Full Text] [Related]

  • 7. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T, Yakoub MA, Chandler A, Christ AB, Yang G, Ouerfelli O, Rajasekhar VK, Yoshida A, Kondo H, Hata T, Tazawa H, Dogan Y, Moore MAS, Fujiwara T, Ozaki T, Purdue E, Healey JH.
    Mol Cancer Ther; 2021 Aug 29; 20(8):1388-1399. PubMed ID: 34088832
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP, Ning WR, Jiang ZZ, Peng ZP, Zhu LY, Zhuang SM, Kuang DM, Zheng L, Wu Y.
    J Hepatol; 2019 Aug 29; 71(2):333-343. PubMed ID: 31071366
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis.
    Ke M, Zhang Z, Cong L, Zhao S, Li Y, Wang X, Lv Y, Zhu Y, Dong J.
    Biomed Pharmacother; 2019 Dec 29; 120():109523. PubMed ID: 31655310
    [Abstract] [Full Text] [Related]

  • 12. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J, Feng W, Sun M, Huang W, Wang G, Chen X, Yin Y, Chen X, Zhang B, Nie Y, Fan D, Wu K, Xia L.
    Gastroenterology; 2024 Jul 29; 167(2):264-280. PubMed ID: 38417530
    [Abstract] [Full Text] [Related]

  • 13. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
    Li Y, Liu H, Zhao Y, Yue D, Chen C, Li C, Zhang Z, Wang C.
    Thorac Cancer; 2021 Oct 29; 12(20):2698-2709. PubMed ID: 34423566
    [Abstract] [Full Text] [Related]

  • 14. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.
    Li X, Gao L, Wang B, Hu J, Yu Y, Gu B, Xiang L, Li X, Li H, Zhang T, Wang Y, Ma C, Dong J, Lu J, Lucas A, Chen H.
    J Immunother Cancer; 2024 Jul 25; 12(7):. PubMed ID: 39060025
    [Abstract] [Full Text] [Related]

  • 15. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H, Shen J, Lu K.
    Biochem Biophys Res Commun; 2017 Apr 29; 486(2):239-244. PubMed ID: 28254435
    [Abstract] [Full Text] [Related]

  • 16. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J, Zhang N, Sun H, Su L, Zhang C, Xu H, Feng J, Wang M, Chen J, Liu L, Shan J, Shen J, Yang Z, Wang G, Zhou H, Prieto J, Ávila MA, Liu C, Qian C.
    Gastroenterology; 2020 Feb 29; 158(3):664-678.e24. PubMed ID: 31678303
    [Abstract] [Full Text] [Related]

  • 17. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, Zhong X, Zimmers TA, Ostrowski MC, Ludwig T, Bloomston M, Bekaii-Saab T, Lesinski GB.
    Gut; 2018 Feb 29; 67(2):320-332. PubMed ID: 27797936
    [Abstract] [Full Text] [Related]

  • 18. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J.
    Gastroenterology; 2017 Oct 29; 153(4):1107-1119.e10. PubMed ID: 28648905
    [Abstract] [Full Text] [Related]

  • 19. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
    Wang R, Guo H, Tang X, Zhang T, Liu Y, Zhang C, Yu H, Li Y.
    Inflammation; 2022 Feb 29; 45(1):308-330. PubMed ID: 34536158
    [Abstract] [Full Text] [Related]

  • 20. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY, Xu T, Fang Y, Ye YP, Li ZJ, Ren FG, Lu SY, Zhang XF, Wu RQ, Lv Y, Dong J.
    Cancer Lett; 2021 Aug 10; 513():14-25. PubMed ID: 33992711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 165.